<DOC>
	<DOCNO>NCT00626704</DOCNO>
	<brief_summary>This phase 1/2 , multicenter , randomize , double-blind , placebo-controlled trial design evaluate efficacy safety AMG 655 combine doxorubicin compare doxorubicin alone subject previously untreated , locally advanced metastatic , unresectable soft tissue sarcoma .</brief_summary>
	<brief_title>Phase 1b/2 Study AMG 655 With Doxorubicin First-Line Treatment Unresectable Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm soft tissue sarcoma Locally advance , recurrent , metastatic , unresectable disease Measurable disease accord modify RECIST ECOG performance status 0 1 Men woman least 18 year age Adequate hematological , renal , hepatic , coagulation function Prior treatment anthracyclines Uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>Locally Advanced Metastatic , Unresectable Soft Tissue Sarcoma</keyword>
	<keyword>AMG 655</keyword>
	<keyword>STS</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Death receptor</keyword>
	<keyword>TRAIL receptor</keyword>
	<keyword>Apoptosis</keyword>
</DOC>